HMS Capital Management’s Pfizer PFE Stock Holding History

HMS Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,797	Closed	-$210K	–	115
2022 Q3	$210K	Hold	4,797	–	–	0.13%	114
2022 Q2	$252K	Buy	+4,797	New	+$244K	0.13%	105
2019 Q3	–	Sell	-1,729	Closed	-$71K	–	269
2019 Q2	$71K	Buy	+1,729	New	+$68.7K	0.03%	192
2018 Q4	–	Sell	-4,806	Closed	-$201K	–	208
2018 Q3	$201K	Buy	+4,806	New	+$185K	0.1%	174

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HMS Capital Management's PFE Position: Q4 2022 in Review

HMS Capital Management sold out of Pfizer (PFE) in Q4 2022, closing a stake of 4,797 shares — an estimated $210K sold.

HMS Capital Management first reported a position in PFE in Q3 2018 and held it in 4 quarters. The position peaked at $252K in Q2 2022. 3,265 funds tracked by Wall St. Rank hold PFE as of Q4 2022.

HMS Capital Management reported no remaining Pfizer position as of Q4 2022 after selling out during the quarter.
HMS Capital Management sold 4,797 Pfizer shares in Q4 2022, an estimated $210K.
HMS Capital Management first reported a position in Pfizer in Q3 2018 and held it in 4 quarters.
HMS Capital Management's Pfizer position peaked at $252K in Q2 2022.
3,265 funds tracked by Wall St. Rank held Pfizer as of Q4 2022.

Based on HMS Capital Management's 13F filing for Q4 2022, filed 23 Jan 2023.